olanzapine-fluoxetine-combination and Hyperprolactinemia

In patients from two clinical trials, we investigated the associations of single nucleotide polymorphisms (SNPs) in candidate genes with prolactin level changes during treatment with olanzapine/fluoxetine combination. In both cohorts, three dopamine receptor D2 (DRD2) SNPs were associated with prolactin changes. DRD2 may influence susceptibility to hyperprolactinemia associated with antipsychotic treatment.

Topics: Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Depression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Fluoxetine; Genome-Wide Association Study; Humans; Hyperprolactinemia; Male; Middle Aged; Polymorphism, Single Nucleotide; Prolactin; Receptors, Dopamine D2; White People; Young Adult